Regrowing limbs, a cure for AML found at the bottom of the ocean and software for data centres to use 25% less energy are all more science than fiction thanks to these 10 spinouts.

Yamaha Motor's sophomore Exploratory Fund brings the amount it has committed to corporate VC to $300m in the past five years.

Cancer survival rates have increased dramatically over the past century, but immunotherapies are not a holy grail — yet.

Seed-stage investor High-Tech Gründerfonds secured backing from a range of German corporates for its fourth fund, taking its total capital under management past €1.3bn.

Managing partner Vijay Patel tells us why CVS Health Ventures has launched a growth fund as its parent makes a big primary care play.

A cure for diabetes, food made from CO2 and a wound dressing that kills superbugs are all a step closer to reality thanks to these 10 spinouts.

CVC veteran Eric Steager has left Touchdown Ventures and joined Purdue University subsidiary Purdue Ventures as managing director.

GV helped head up a 35-strong investor network backing Curie, which has raised $520m to bring CVC-like strategic help to its seed-stage drug developer portfolio.

Boston-based startup General Prognostics is developing a digital biomarker platform for heart disease patients. It is one of a growing number of emerging blood-related tech startup raising funding.

How do you stop AI from being racist? What if you could diagnose autism at birth using a single strand of hair? Here are 10 spinouts doing this and more.